Fresenius Medical Care AG & Co. KGaA (FME.DE)
| Previous close | 37.79 |
| Open | 37.85 |
| Bid | 37.42 x 38700 |
| Ask | 37.45 x 105300 |
| Day's range | 37.34 - 38.12 |
| 52-week range | 30.16 - 49.62 |
| Volume | |
| Avg. volume | 433,463 |
| Market cap | 10.98B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | 22.01 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.19 (3.15%) |
| Ex-dividend date | 17 May 2024 |
| 1y target est | N/A |
- PR Newswire
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
- PR Newswire
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards. The glasses stream visual and acoustic recordings as users inte
- PR Newswire
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.
